论文部分内容阅读
单剂水痘疫苗在儿童中有较好的耐受性和免疫原性,它的广泛使用降低了水痘的发病人数,但同时增大了初免无应答人群晚年发生水痘的危险,而且也不能肯定免疫力能否维持终身。本研究旨在评价初免后6年加强1剂水痘疫苗的安全性和免疫应答情况。 作者对4～6年前接种过水痘疫苗的419名儿童和青少年,于三角肌区皮下注射约含3300空斑形成单位的OKa/Merck减毒活疫苗。分别在接种的0、7～10天、6周和3个月采血,用糖蛋白酶固相ELISA(gpELISA)测抗水痘-带状疱疹病毒(VZV)抗体,滴度>0.3判为阳性;对74名对象进行VZV特异性淋巴细胞增殖试验测定细胞免疫应答,刺激指
The single-dose varicella vaccine is well tolerated and immunogenic in children and its widespread use reduces the incidence of chickenpox but at the same time increases the risk of developing chickenpox in later-life non-responders and is uncertain Immune to maintain life. The aim of this study was to evaluate the safety and immune response of one dose of varicella vaccine six years after initiation. The authors vaccinated 419 children and adolescents who had been vaccinated against chickenpox 4-6 years ago and injected subcutaneously an OKa / Merck live attenuated vaccine containing 3,300 plaques in the deltoid area. Blood samples were collected at 0, 7-10 days, 6 weeks and 3 months after inoculation. Anti-varicella-herpes zoster virus (VZV) antibody was detected by gp ELISA and the titer was> 0.3. Seventy-four subjects underwent VZV-specific lymphocyte proliferation assays to measure cellular immune responses